Rury R Holman is an expert in Endocrinology at Churchill Hospital (United Kingdom). As of October 2026, ScienceLeadR ranks Rury R Holman in the top 1% of experts worldwide for Diabetes Mellitus, Glucose Metabolism Disorders and Hyperglycemia. Rury R Holman has authored 586 publications, the most recent in 2026, and is an investigator in 15 clinical trials. SLR score: 2,270 (community average: 125). How the SLR is computed.

LeadR Profile

Rury R Holman Churchill Hospital United Kingdom
2 270 ScienceLeadR Reputation 2270
Network Map

Endocrinology

Subspecialties: Cardiology - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1997 - 2026

Source: PubMed

University of Oxford

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 586

Citations

Citations: 97 504 1st author: 51 Last author: 162 Unique author: 14


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
α-Hydroxybutyrate and Cardiovascular Outcomes in People Living With Type 2 Diabetes: An EXSCEL Post Hoc Analysis.
PMID 42935187 — diabetes mellitus, cardiovascular diseases, diabetes complications, diabetes mellitus, type 2
Diabetes Obes Metab20260
Semaglutide treatment fails but might prevent Alzheimer's disease.
PMID 42594906 — alzheimer disease, therapeutics, semaglutide
Lancet Top journal20261
A Validated, Modifiable Proteomic Score from the EXSCEL Trial Predicts Cardiovascular Events in Diabetes.
PMID 42390946 — diabetes mellitus, biomedical research, multiple chronic conditions, therapeutics, plasma, diabetes mellitus, type 2
JCI Insight20260
Leveraging external controls in clinical trials: estimands, estimation, assumptions.
PMID 42332981 — bias, propensity score, therapeutics, pharmacokinetics
J Biopharm Stat20260
To Cluster or Not to Cluster? A Comparison of Approaches to Targeting Type 2 Diabetes Glucose-Lowering Therapy in the TriMaster Crossover Trial.
PMID 42312889 — diabetes mellitus, insulin, pharmaceutical preparations, therapeutics, diabetes mellitus, type 2
Diabetes Care20261

Clinical Studies 15

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 3 9
Phase 4 4
N/A 2

By status:

Completed 15

By type:

Interventional 13
Observational 2

By Monocentric/Multicentric:

monocentric 6
multicentric2to4 0
multicentric5to9 0
multicentricup10 9

Main Topics

Cohort/Consortium Investigators 1

LeadR Networks

Main global connection map